Nucleic acids and methods of treatment for cystic fibrosis
US12070509B2 · kind B2 · utility
0Cited by
11References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 30, 2021 |
| Grant date | Aug 27, 2024 |
| Priority date | — |
| Expiry date | Jul 21, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/0041
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Nucleotides encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein are provided herein. Also describe are mRNA constructs that can be used to express CFTR protein in vitro or in vivo. The mRNA constructs can be formulated in a lipid formulation and administered via inhalation to treat cystic fibrosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.